GGrantIndex
← Leaderboards

Barry Neal Kreiswirth

Univ Of Med/Dent Of Nj-Nj Medical School

$16,093,291
Attributed
$16,093,291
Total exposure
8
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.7M · FY201025
$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,093,291 · 8

By mechanism

R01$11,393,737 · 2
U19$2,226,528 · 1
R21$897,367 · 2
U01$874,998 · 1
R56$558,370 · 1
D43$142,291 · 1

Top collaborators

No co-investigators on record.

Others in their field

Top investigators on “Infection

Research focus

InfectionResistanceMolecularAntibiotic ResistanceCollectionGenesMulti-Drug ResistanceAreaPathogenHospitalsGeneticGenomicsResponseOrganismResistant StrainComplexCellsCarbapenemsMutantBasePharmaceutical PreparationsResistance MechanismDiagnosticReporting

Grant awards (29)

Dissecting the molecular targets to overcome beta-lactam resistance in M. abscessus complex$901,706
R01 · FY2025 · AI · contact PI
Dissecting the host-plasmid interplay to unravel the spread of ESBL-producing K. pneumoniae$874,998
U01 · FY2025 · AI · contact PI
Core D In vitro Screening$539,861
U19 · FY2023 · AI · contact PI
A dual-beta-lactam strategy for treating multidrug resistant M abscessus$809,943
R01 · FY2022 · AI · contact PI
Core D In vitro Screening$376,800
U19 · FY2022 · AI · contact PI
A dual-beta-lactam strategy for treating multidrug resistant M abscessus$812,809
R01 · FY2021 · AI · contact PI
The molecular basis of the carbapenem resistance epidemic$667,413
R01 · FY2021 · AI · contact PI
Core D In vitro Screening$365,302
U19 · FY2021 · AI · contact PI
The molecular basis of the carbapenem resistance epidemic$1,114,475
R01 · FY2020 · AI · contact PI
A dual-beta-lactam strategy for treating multidrug resistant M abscessus$820,613
R01 · FY2020 · AI · contact PI
Core D In vitro Screening$374,400
U19 · FY2020 · AI · contact PI
The molecular basis of the carbapenem resistance epidemic$1,016,803
R01 · FY2019 · AI · contact PI
A dual-beta-lactam strategy for treating multidrug resistant M abscessus$890,074
R01 · FY2019 · AI · contact PI
Core D In vitro Screening$570,165
U19 · FY2019 · AI · contact PI
Unraveling colistin resistance in Klebsiella pneumoniae$221,375
R21 · FY2019 · AI · contact PI
The molecular basis of the carbapenem resistance epidemic$991,002
R01 · FY2018 · AI · contact PI
Unraveling colistin resistance in Klebsiella pneumoniae$238,500
R21 · FY2018 · AI · contact PI
The molecular basis of the carbapenem resistance epidemic$647,565
R01 · FY2017 · AI · contact PI
The molecular basis of the epidemic blaKPC gene Klebsiella$544,800
R01 · FY2015 · AI · contact PI
The molecular basis of the epidemic blaKPC gene Klebsiella$564,497
R01 · FY2014 · AI · contact PI
A rapid molecular approach to determine PZA susceptibility$201,992
R21 · FY2014 · AI · contact PI
The molecular basis of the epidemic blaKPC gene Klebsiella$762,236
R01 · FY2013 · AI · contact PI
A rapid molecular approach to determine PZA susceptibility$227,527
R21 · FY2013 · AI · contact PI
Analysis of XDR-TB and MDR-TB strains: safety, diagnosis and pathogenesis$142,291
D43 · FY2013 · TW · contact PI
The molecular basis of the epidemic blaKPC gene Klebsiella$76,308
R01 · FY2013 · AI · contact PI
A rapid molecular approach to determine PZA susceptibility$7,973
R21 · FY2013 · AI · contact PI
The molecular basis of the epidemic blaKPC gene Klebsiella$536,305
R01 · FY2012 · AI · contact PI
The molecular basis of the epidemic blaKPC gene Klebsiella$237,188
R01 · FY2011 · AI · contact PI
The molecular basis of epidemic blaKPC Klebsiella pneumoniae and Enterobacteriace$558,370
R56 · FY2010 · AI · contact PI